Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Dasatinib is a tyrosine kinase inhibitor effective against Bcr-Abl-positive leukemia.
• The precise mechanism of dasatinib-induced cell death, especially in vivo, remains incompletely understood.
• Autophagy, a cellular degradation process, plays a dual role in cell survival and drug resistance.

Purpose of the Study:

• To investigate the role of autophagy in dasatinib's mechanism of action in Bcr-Abl-positive leukemia.
• To determine if dasatinib induces autophagy in leukemia cells infiltrating the central nervous system (CNS).

Main Methods:

• Utilized Bcr-Abl-positive leukemia cell lines.
• Employed an immunodeficient mouse model of human Bcr-Abl-positive leukemia with CNS infiltration.
• Analyzed autophagy induction in bone marrow (BM) and cerebrospinal fluid (CSF) samples.

Main Results:

• Dasatinib treatment induced autophagy in Bcr-Abl-positive leukemia cell lines.
• Autophagy induction was observed in leukemic cells within the CNS of the mouse model.
• Autophagy was detected in both bone marrow and cerebrospinal fluid.

Conclusions:

• Autophagy induction is a mechanism contributing to dasatinib's effect on Bcr-Abl leukemia cells.
• This is the first study demonstrating autophagy induction in CNS-infiltrating leukemic cells.
• Targeting autophagy presents a potential novel therapeutic strategy for Bcr-Abl leukemia with CNS involvement.